Neurotrope — Investor Presentation (January 2015)
20 slides from Neurotrope's investor presentation, Jan 14, 2015
Slide 1: Neurotrope, Inc. Targeting Neurologic Disease
Neurotrope, Inc. OTCQB: NTRP Targeting Neurologic Disease www.neurotropebioscience.com
Slide 2: Safe Harbor Statement
Safe Harbor Statement 2 Cautionary language regarding forward - looking statements Certain statements in this presentation, particularly those pertaining to our strategy, constitute forward - looking statements . Such statements are based upon the current beliefs and expectations of management and a
Slide 3: Neurotrope
3 Neurotrope Neurotrope is a biopharmaceutical company developing b ryostatin for treatment of neurodegenerative disease including Alzheimer’s disease and o rphan drug indications.
Slide 4: Investment Considerations
4 Investment Considerations • Exploiting licensed technology from the Blanchette Rockefeller Neurosciences Institute (BRNI): ~ $ 200 million spent to - date by NCI, BRNI and NTRP to advance technology • Phase 2a safety trial dosing for Alzheimer’s disease (AD) completed • Planning Phase 2b clinical
Slide 5: Unique Scientific Approach
5 Unique Scientific Approach • Unique and promising approach to treatment of neurodegenerative disorders • Unlike previously failed treatments for Alzheimer’s disease, b ryostatin does not target Amyloid or Tau directly but offers a novel approach • Developed by Dr. Dan Alkon, Scientific Director an
Slide 6: Unique Scientific Approach: Bryostatin activates PKCe
6 Unique Scientific Approach • Bryostatin activates Protein Kinase C epsilon (PKCe) • PKCe is an upstream modulator of protein synthesis related to learning, memory and synaptogenesis • In patients with moderate to severe AD and other neurodegenerative diseases, PKCe activity is reduced resulting in
Slide 7: Clinical Program
7 Clinical Program • Previous clinical program in cancer patients conducted by the National Cancer Institute • Extensive clinical exposure, > 1,000 patients • NTRP completed dosing Phase 2a safety study • Double - blinded, placebo controlled • Results expected Q1 2015 • NTRP planning Phase 2b Proof
Slide 8: Orphan Diseases
8 Orphan Diseases • Fragile X Syndrome • Most common cause of inherited intellectual disability • S ingle gene defect resulting in significant impairment in cognition with significant behavioral manifestations including autistic features • ~ 1:4,000 males / ~ 1:6,000 females • Niemann - Pick Type C
Slide 9: Market Potential – AD and Orphan Drugs
9 Market Potential – AD and Orphan Drugs • Alzheimer’s disease – Multi - billion dollar market potential • 5 million individuals suffer with AD in the U.S. • Cost of medication between $650 and $4,000 annually • Minimal clinical benefit • Multi - billion dollar U.S. alone market opportunity • Fragil
Slide 10: Alzheimer's Diagnostic
10 Alzheimer’s Diagnostic • Developed by Dr. Alkon at BRNI • Relates to abnormalities in PKC epsilon activity in skin fibroblasts • Further validation in a prospective trial to be conducted.
Slide 11: Advancing Neurotrope's Pipeline
11 Advancing Neurotrope’s Pipeline • Second generation molecules • Bryologs - Modified / improved bryostatin • Exclusive licensing agreement with Stanford University for broad use including neurodegenerative diseases • Dr. Paul Wender at Stanford developing specific bryologs for NRTP for use in AD a
Slide 12: Near-Term Milestones - 2015
12 Near - Term Milestones - 2015 • Q1 2015 • Results of Phase 2a safety study • Complete current Niemann - Pick Type C pre - clinical animal studies on b ryostatin with Mt. Sinai • File for orphan drug designation for Fragile X • Enroll additional Compassionate Use patients • Q2 2015 • Initiation of
Slide 13: Near-Term Milestones 2015
13 Near - Term Milestones 2015 • Q3 2015 • Develop clinical strategy for Niemann - Pick Type C with regulatory agency • File for orphan drug designation for Niemann - Pick Type C • Enroll additional Compassionate Use patients • Site initiation and patient screening for AD Phase 2b clinical trial • Q
Slide 14: Trading and Capitalization
14 Trading and Capitalization Current Capitalization Shares Common Stock 24.0 MM Series A Convertible Preferred Stock (Convertible @ $1.00 / share) 21.4 MM Options & Warrants Outstanding (Weighted Avg. E.P. $1.21 / share) 9.4 MM Total fully diluted shares 54.8 MM Trading Information Ticker symbol (O
Slide 15: Neurotrope Management Team
15 Neurotrope Management Team • Charles S. Ramat – President, Chief Executive Officer and Board member • Extensive operational and general business experience in both public and private companies • Industry focus - Biotechnology, medical devices, commercial finance, real estate • Paul Freiman – Chai
Slide 16: Neurotrope Management Team
16 Neurotrope Management Team • Dr . Dan Alkon – Chief Scientific Officer • Graduate of Cornell M edical S chool • 30 year career as Medical D irector and L ab Chief in US NIH specializing in memory disorders • 14 years as founding Scientific D irector of BRNI • Dr. Warren W. Wasiewski – Chief Medic
Slide 17: Select Clinical Advisory Board – Six Members
17 Select Clinical Advisory Board – Six Members • Dr. Jeffrey L. Cummings, MD, ScD, CCF - Chairman • Director of Cleveland Clinic Lou Ruvo Center for Brain Health • Professor of Neurology and Psychiatry, D irector of MSE Center for AD Research and Director of the DFJ Center for Neurotherapeutics at
Slide 18: Select Clinical Advisory Board
18 Select Clinical Advisory Board • Dr. Cristina Sampaio, MD, PhD • Chief Medical Officer at CHDI Foundation • Professor of Clinical Pharmacology and Therapeutics University of Lisbon, Portugal • Former member of the Committee of Proprietary Medicinal Products and the Scientific Advice Working Party
Slide 19: Summary
19 Summary • Unique potential therapy for treatment of moderate to severe Alzheimer’s disease • Phase 2 clinical trials in AD • Commercial diagnostic test in development to satisfy unmet medical need • Pursuing multiple orphan drug disease states with no effective treatments – have significant marke
Slide 20: Kreurotrope
Kreurotrope 20 BioScience’